SPRY icon

ARS Pharmaceuticals

184 hedge funds and large institutions have $960M invested in ARS Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 58 increasing their positions, 54 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10:

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more funds holding

Funds holding:

4.37% more ownership

Funds ownership: 73.37%77.73% (+4.4%)

7% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 54

41% less call options, than puts

Call options by funds: $2.67M | Put options by funds: $4.54M

Holders
184
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$2.67M
Puts
$4.54M
Net Calls
Net Calls Change

Top Buyers

1 +$16.5M
2 +$13.8M
3 +$12.9M
4
Aberdeen Group
Aberdeen Group
United Kingdom
+$12.6M
5
LCS
Levin Capital Strategies
New York
+$8.77M

Top Sellers

1 -$12.1M
2 -$9.04M
3 -$6.53M
4
UBS Group
UBS Group
Switzerland
-$5.3M
5
RA
Royce & Associates
New York
-$3.61M